Small biotechs in the US that are thinking about expansion into Europe but face choosing between the UK and the EU as their base following Brexit are realizing that a home in Northern Ireland could give them the best of both worlds.
Northern Ireland Offers Biotechs Gateway To Both UK And EU
US Firms Weighing Up Attraction
Countries from all over the world were plying their wares as desirable biotech clusters at the recent BIO meeting in Boston and Northern Ireland made a strong case for its potential as a prime location for life sciences starts-ups.
More from Start-Ups & SMEs
More from Business
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
• By
A decision from the FDA is due by 28 September.